Trial Profile
A Comparative, Proof of Concept Study, Comprising of a Pilot Phase Bioavailability Study Part and a Randomised, Cross-over Food-effect Study Part of 'XS003' and Originator in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2018
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia; Eosinophilia; Gastrointestinal stromal tumours; Malignant melanoma; Precursor cell lymphoblastic leukaemia-lymphoma; Skin cancer
- Focus Pharmacokinetics; Proof of concept
- Sponsors XSpray Microparticles; Xspray Pharma
- 10 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 20 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 16 Mar 2014 New trial record